SENATOR Deirdre Clune challenged Barry O’Leary CEO of the IDA on the organisation’s jobs strategy with relation to the pharmaceutical industry while he addressed the Oireachtas Committee on Jobs, Enterprise and Innovation today.
The pharmaceutical industry in Ireland and globally is under extreme pressure as many high profile drugs come off of patent. Cork has seen considerable job losses in this sector, notably within the two Pfizer plants.
Over the weekend Barry O’Leary the CEO of the IDA expressed his confidence that a number of international pharmaceutical players are to make investment deals in Ireland before the New Year.
Senator Clune is calling for the IDA to consider locating these investments where jobs have been previously lost.
“The nature of the pharmaceutical industry is ever changing and this can result in job losses however this could present a positive opportunity.
“It is vital that the IDA is committed to focusing on areas which have lost jobs in pharmaceuticals because the labour force already has the skills necessary to work in the industry.
“Although Barry O’Leary would not comment on specific companies it is important that the issue was raised with him.
“While many of the high-profile drugs are coming off patent the IDA has alluded to opportunities for jobs and growth within this sector regarding alternative cheaper and generic drugs.
“However the issue of whether the new jobs within the industry will be replacing traditional workers remains to be seen.
“This is of key importance to Cork as there could be an excellent opportunity to regain jobs which were lost in this area.
“I hope that Cork can become Ireland’s hub for the pharmaceutical industry and continues to secure investments like the jobs created by Eli Lilly earlier this year.”